SCHEMBL24105192

SCHEMBL24105192

COc1ccc(-c2cnc3c(Nc4ccc(NC(=O)CN5CCNCC5)c(C)c4)nccn23)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK6 Q13882 3/20 0.47
▸ CCNE2 O96020 1/20 0.43
▸ CDK4 P11802 1/20 0.43
▸ CCND1 P24385 1/20 0.43
▸ CCNE1 P24864 1/20 0.43
▸ CDK2 P24941 1/20 0.43
▸ KDR P35968 8/20 0.41
▸ AURKB Q96GD4 1/20 0.40
▸ MAP4K1 Q92918 1/20 0.40
▸ ESR1 P03372 2/20 0.40
▸ PDGFRB P09619 2/20 0.40
▸ TTK P33981 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24104675 0.90 PTK6 (0.50) PTK6KDRAURKBMAP4K1MEN1
SCHEMBL24104678 0.84 TTK (0.44) PTK6KDRTTKALDH1A1MAPT
SCHEMBL30168196 0.84 TTK (0.44) PTK6KDRTTKALDH1A1MAPT
SCHEMBL24104823 0.83 TTK (0.40) PTK6MAP4K1TTKMEN1KMT2A
SCHEMBL30167878 0.82 TTK (0.41) PTK6KDRTTKALDH1A1MAPT
SCHEMBL24105238 0.82 TTK (0.41) PTK6KDRTTKALDH1A1MAPT
Hydrochloric Acid SCHEMBL30168139 0.81 TTK (0.40) PTK6KDRTTKALDH1A1MAPT
SCHEMBL22124684 0.80 PTK6 (0.47) PTK6AURKBTTK
SCHEMBL25447388 0.80 TTK (0.40) PTK6TTK
SCHEMBL24104677 0.80 SRC (0.44) PTK6AURKBTTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230141403-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-05-11 — — US disclosed
US-20230141403-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-05-11 — — US disclosed
CN-115667264-A Novel imidazo-pyrazine derivatives 豪夫迈·罗氏有限公司 2023-01-31 — — CN disclosed
WO-2021249893-A1 NOVEL IMIDAZO-PYRAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2021-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230141403-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES XDH, MYD88, IKZF3 PTK6 2213/4885CCNE2 1440/4885CDK4 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback